Previous 10 | Next 10 |
TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver multiple presentations at the 2022 VEITH Symposium, which is being ...
InspireMD, Inc. (NSPR) Q3 2022 Earnings Conference Call November 8, 2022 08:30 AM ET Company Participants Chuck Padala - IR, LifeSci Advisors Marvin Slosman - CEO Craig Shore - CFO Conference Call Participants Benjamin Haynor - Alliance Global Partner...
- Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 - - Announced strategic pa...
InspireMD press release ( NASDAQ: NSPR ): Q3 GAAP EPS of -$0.58 beats by $0.15 . Revenue of $1.43M (+33.6% Y/Y) beats by $0.03M . Cash and cash equivalents of $3.93M as at Sep.30. For further details see: InspireMD GAAP EPS of -$0.58 beats by $0.15, r...
TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2022 financial res...
TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeuti...
NAMSA , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc . (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of st...
InspireMD, Inc. (NSPR) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Chuck Padala - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjam...
InspireMD press release ( NASDAQ: NSPR ): Q2 GAAP EPS of -$0.59 beats by $0.14 . Revenue of $1.53M (+48.5% Y/Y) beats by $0.33M . For further details see: InspireMD GAAP EPS of -$0.59 beats by $0.14, revenue of $1.53M beats by $0.33M
- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed...
News, Short Squeeze, Breakout and More Instantly...
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prev...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...